glp-1 cardiovascular outcomes 2025 news Agonists in Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies GLP-1 trends 2025: real-world data,

Make 5 jars on Sunday for the work week

This is because the medication is still undergoing further trials to ensure its safety and suitability for long-term use

It depends on your plan and diagnosis: Most Illinois insurance plans cover GLP-1s for diabetes (Ozempic, Mounjaro.) Coverage for obesity (Wegovy, Zepbound) varies significantly Blue Cross Blue Shield of Illinois: Variable by plan, often requires BMI 30+ and prior weight loss attempts UnitedHealthcare: Many plans exclude obesity medications entirely Aetna: Some plans cover with prior authorization Illinois Medicaid: Covers for diabetes, limited obesity coverage We help with prior authorizations and appeals

Data from the forthcoming FLOW trial are also awaited

Lilly said most cases involving paresthesia were mild and rarely led to treatment discontinuation

Clinical trial data from the STEP 1 extension study showed that after discontinuing semaglutide 2.4 mg, approximately two-thirds of weight loss was regained within one year